Fredun Pharmaceuticals Funding Approved – Analyzed
Fredun Pharmaceuticals announced a significant boost to its finances on December 29, 2025. The company’s board decided to raise money through two separate deals. This means they’ll have more money to develop new medicines and grow their business.
Key Points
- Raised Rs 80.54 crore through equity share issuance.
- Issued 6,44,360 equity shares at Rs 1250 each.
- Secured Rs 68.95 crore via convertible warrants issuance.
- 5,51,600 convertible warrants issued at Rs 1250 per warrant.
- Rs 17.23 crore subscribed to warrants (25% of issue price).
- Total funding raised: Rs 149.49 crore from both deals.
Equity Share Issuance Details
The company sold 6,44,360 new shares to investors. Each share was sold for Rs 1250, which included a premium of Rs 1240. This means investors paid more than the basic value of the share. The total amount raised from this sale is Rs 80.54 crore.
Convertible Warrant Details
Fredun Pharmaceuticals also sold 5,51,600 convertible warrants. These warrants let investors buy shares later, at a set price of Rs 1250 per warrant. Investors paid Rs 312.50 upfront, representing 25% of the warrant’s price. This initial payment secured Rs 17.23 crore.
The funds will be used to support Fredun’s ongoing research and development efforts, allowing them to pursue new drug discoveries and expand their product portfolio. The company’s leadership believes this investment will accelerate growth and deliver value to shareholders.
“Strategic investment drives innovation and future growth for Fredun Pharmaceuticals.”
